Deals

ePharmaSolutions Received a Strategic Investment from Arsenal Capital Partners and WIRB-Copernicus Group September 24, 2014

Overview

On September 24, 2014, Crosstree Capital Partners announced that WIRB-Copernicus Group (WCG) has made a strategic investment in ePharmaSolutions (ePS).

WCG is the world’s largest provider of regulatory and ethical review services for clinical research, including Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review.

EPS is a leading provider of eClinical solutions and specialty clinical services that help improve the way trial sites are selected, trained, activated and managed to exceed enrollment goals.

Significance

The combination of WCG’s site and investigator network, and the workflow and integration technologies of ePS creates not just a cross-functional platform, but a collaborative ecosystem that spans sponsors, CROs, sites, investigators, patients and IRBs.

WCG now has access to ePS’ proprietary solutions, including a cloud-based enterprise Clinical Trial Portal (CTP) and Electronic Trial Master File (eTMF), which are used by 350,000 clinical research professionals across 130 countries.

ePS will continue to operate independently at its current locations, but WCG will support ePS as it continues to expand its platform solution with access to capital, complimentary clinical expertise, corporate support, and integration of its technologies within the WCG family of companies.

Crosstree’s Role

Crosstree Capital Partners represented ePS in its transaction with WCG.

Sub-Sector

Pharma Services
Healthcare Technology

Type

Recapitalization / Restructuring

Deal Tags

Clinical Trials
Pharma Development
Healthcare
IRB
Patient and Site Engagement
PE Platform Transactions
CRO
Pharma Consulting